Sontag Family Trust

Myosin Therapeutics is a biopharmaceutical company focused on developing novel medications that target cellular motor proteins. It leverages molecular machines that convert energy into mechanical work inside cells to create therapies aimed at treating central nervous system disorders and other diseases, including cancer. The company concentrates on advancing pharmacotherapies that modulate motor protein activity to impact disease pathways and address significant unmet medical needs.

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.

MimiVax is a clinical-stage biotechnology company focused on developing immunotherapeutic vaccines and targeted therapies for cancer treatment. Its flagship product, SurVaxM, targets survivin, a protein present in most cancers, aiming to disrupt tumor growth and recurrence.

Modifi Bio develops oncology therapeutics based on direct DNA modification. The company pursues a platform that modifies tumor DNA to render cancer cells irreparable while preserving healthy cells, aiming to disrupt conventional oncology drug development.

Kiyatec, LLC is a biotechnology company specializing in the development of advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. Founded in 2005 and based in Greenville, South Carolina, Kiyatec employs its proprietary 3DKUBE technology platform to create functional 3D models using patients' own living tumor cells. This innovative approach allows for the evaluation of various cancer therapies, providing insights into drug toxicity and efficacy before clinical trials. The company offers a range of services, including drug response profiling, predictions of patient responses to therapies, and cell-based assays for oncologists. Additionally, Kiyatec collaborates with biopharma clients on standard and custom assays and conducts research funded by the National Cancer Institute to develop 3D cell culture models for several types of cancer, such as breast cancer, glioblastoma, and lung cancer. By modeling complex human biology and simulating in vivo conditions, Kiyatec aims to improve treatment selection for cancer patients and support the development of medical devices and therapeutic drugs.

AiM Medical Robotics is a company focused on developing an innovative robotic system designed for neurosurgical procedures. This unique system is MRI compatible, allowing patients to receive treatment while inside the MRI scanner, which provides physicians with real-time imaging feedback to enhance surgical outcomes. The robotic platform integrates surgical planning with MR functional robotics, ensuring precise trajectory guidance during procedures. AiM Medical Robotics aims to assist in the treatment of various conditions, including Parkinson's disease, epilepsy, tremors, and brain cancer, ultimately improving the quality of care for patients undergoing neurosurgery for functional brain disorders.

Agrivida, Inc. is a biotechnology company specializing in animal health and nutrition through the development of innovative feed additives for poultry, swine, dairy and beef cattle, and aquaculture. Founded in 2003 and based in Four Seasons, Missouri, Agrivida utilizes its proprietary GRAINZYME technology to produce enzymes directly within corn kernels, offering a natural and effective method to enhance animal diets. This platform enables the integration of beneficial enzymes such as phytase and glucanase, which improve nutritional efficiency and reduce the environmental impact of livestock production. Agrivida's solutions aim to promote healthier food production while delivering economic benefits to its clients in the agricultural sector.

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.